◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › ARWR

Arrowhead Pharmaceuticals, Inc. (ARWR) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-26

Arrowhead Pharmaceuticals, Inc. (ARWR) operates in the Biotechnology industry and is headquartered in Pasadena, United States with about 711 employees. Its market capitalization is roughly $12 billion. In the fiscal year ended 2025-09-30, ARWR reported $829M in revenue and ($2M) in net income.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

Interactive charts & full statements → Open the ARWR valuation workbench →

ARWR Revenue & Earnings History — Annual Income Statement

Income statement2025-09-302024-09-302023-09-302022-09-302021-09-30
Total Revenue$829M$4M$241M$243M
Operating Income (EBIT)$98M($601M)($205M)($178M)
Net Income($2M)($600M)($205M)($176M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARWR Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$74M$264M$256M$28M$543M
Operating Income (EBIT)($141M)$41M$44M($166M)$381M
Net Income($133M)$31M($24M)($175M)$370M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARWR Free Cash Flow History

ARWR Balance Sheet History

Balance sheet2025-09-302024-09-302023-09-302022-09-302021-09-30
Total Assets$1.4B$1.1B$766M$692M
Total Liabilities$882M$949M$478M$274M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ARWR viewer.

Other Companies in Biotechnology

← ARWAll stocksARX →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.